EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT)

485 reported adverse events

Drug classes: Endoglycosidase [EPC] Neonatal Fc Receptor Blocker [EPC]

These side effects are most commonly reported by patients taking EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT):

# Side effect Count
0 MYASTHENIA GRAVIS 68
1 FATIGUE 67
2 ASTHENIA 40
3 DRUG INEFFECTIVE 38
4 FALL 37
5 MUSCULAR WEAKNESS 37
6 INJECTION SITE ERYTHEMA 25
7 MYASTHENIA GRAVIS CRISIS 25
8 CONDITION AGGRAVATED 24
9 HEADACHE 24
See all common reactions for EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT)

EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT) is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 ACTIVITIES OF DAILY LIVING ASSESSMENT 1 0.0500
1 PROCEDURAL HEADACHE 16 0.0390
2 MYASTHENIA GRAVIS CRISIS 25 0.0169
3 CATHETER SITE SCAR 1 0.0167
4 CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY 22 0.0153
5 PROCEDURAL DIZZINESS 4 0.0124
6 BLADDER TRABECULATION 1 0.0123
7 MYASTHENIA GRAVIS 68 0.0084
8 DERMATOCHALASIS 1 0.0068
9 INJECTION SITE EXFOLIATION 4 0.0060
See all enriched reactions for EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT)